Myeloma

From World Cancer Day to top performers and athletes, here is a quick overview of what is making headlines in the cancer space.

Multiple myeloma is a type of blood cancer that originates in the bones. Here’s what you need to know about the disease.

All in all, I’m very pleased with being able to get my oral chemo directly from my clinic’s pharmacy. The staff knows me and they know my doctor.

Toronto’s Jeff Lipton, PhD, MD, FRCPC, shares his thoughts on the outlook for blood cancers.

In an interview with CURE, Filippo Milano, M.D., Ph.D., explains what cord blood transplantation is and why it is important for patients to learn more.

Patients with myeloma who took higher doses of Kyprolis plus dexamethasone tended to have better survival outcomes, according to a recent study.

The combination of Darzalex (daratumumab), Revlimid (lenalidomide) and dexamethasone significantly reduced the risk for disease progression in patients with newly diagnosed multiple myeloma.

New findings could spark change in the way that some patients with multiple myeloma are treated.

Take a look at content from CURE Magazine from 10 years ago to see how the myeloma space – and our magazine in general – has changed!

In the general population, African Americans tend to have poorer myeloma outcomes; however, that may not be the case for veterans.

Hear patient-to-patient advice on navigating the complicated landscape of cancer care (and its costs).

"In the midst of all of the difficulty of trying to deal with something this terrible, having that hope in your back pocket is invaluable to my life and to my family." - Brian Smith, on living with multiple myeloma and participating in Moving Mountains for Multiple Myeloma's recent Iceland trek.

The Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) for use in combination with Pomalyst (pomalidomide) and low-dose dexamethasone, also known as EPd, for the treatment of patients with relapsed/refractory multiple myeloma following two or more prior therapies, including Revlimid (lenalidomide) and a proteasome inhibitor.

Treating people with cancer requires the coordination of complex care, and adding a clinical trial to the mix can pose more challenges.

A recent study found that fatigue reported among newly diagnosed patients with multiple myeloma may predict survival outcomes.

Preliminary findings showed that Revlimid (lenalidomide) significantly prolonged progression-free survival compared with observation in patients with smoldering multiple myeloma.

The Food and Drug Administration has granted a priority review to a new drug application for selinexor (KPT-330) for the treatment of patients with penta-refractory multiple myeloma.

The Food and Drug Admnistration has approved a once-weekly dosing option of Kyprolis (carfilzomib) to use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma.

September is Blood Cancer Awareness month and CURE’s latest issue is dedicated to these diseases. And we have a sneak peek at what’s inside:

A 16-member team, including five patients with multiple myeloma, hiked through Iceland to raise money for disease research in hopes of finding a cure.

Injectable forms of medication may benefit patients with blood cancers.

Previously, there were concerns that older patients would not be able to handle the toxicities of the procedure, or that their stem cells, which are older, would not work as well. But that proved to not be the case.

The FDA has granted a priority review to a supplemental biologics license application (sBLA) for Empliciti (elotuzumab) for use in combination with Pomalyst (pomalidomide) and low-dose dexamethasone (EPd) for the treatment of patients with relapsed/refractory multiple myeloma following two or more prior therapies, including Revlimid (lenalidomide) and a proteasome inhibitor (PI).

See what CURE readers have to say about our previous issues.

A patient's bone health history may offer clues into their myeloma outcomes, according to a recent study.

Understanding these outcomes is important in planning treatments and mitigating the possibility of patients stopping their treatment.

Creating a medical family tree is helpful. If cancer is common, noting which branches include it can help inform decisions.

Here is what one expert says about the right time to start treating relapsed multiple myeloma.

This hike marks the fifth continent to be visited by a Moving Mountains for Multiple Myeloma team